Zimbabwe has declined a major American health deal worth $367m (272 million pounds) over five years because of the United States' demand for sensitive data.
The decision was revealed following a official document dated December was disclosed, revealing that President Emmerson Mnangagwa felt the agreement was "lopsided".
A government spokesman later clarified that the United States was demanding access to genetic material for research and profit but refused to guarantee the resulting advantages from any future treatments.
"We will now turn to the difficult and regrettable task of ending our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had furnished more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has urged more talks to find a deal suitable to both sides so the nation's critical HIV programme can continue.
Broader Background
This rejection comes after a comparable situation in neighbouring Kenya, where a court halted a related health funding agreement following concerns were raised about the security of Kenyans' health data.
After resuming office recently, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
The agency had overseen assistance for the American government, but Trump stated its spending was "wasteful" and his government was pursuing government-to-government agreements to boost transparency and responsibility.
According to statements, 16 nations in Africa have so far signed similar agreements, representing over $18.3bn of fresh investment.
Specifics of the Rejected Deal
The funds for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this partnership could have provided extraordinary advantages for Zimbabwean communities, particularly the 1.2 million men, women and children presently on antiretroviral therapy through American-funded initiatives," the Ambassador commented.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"Our nation was requested to provide its biological resources and data indefinitely, without any corresponding promise of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might be developed from that provided information," he stated.
"Put simply, our country would supply the basic resources for scientific discovery without any assurance that the final treatments would be available to our population if a new pandemic arise."
Sovereignty and Global Health
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were disrupting structures already established via the international health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework designed to deal with potential pandemics.
"This framework is intended to ensure that when a nation provides its data, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised solely by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We encourage continued dialogue with our US partners on how subsequent co-operation could be arranged in a manner that honours the sovereignty and dignity of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the official position, but urged that talks need to persist given that much of the country's HIV programmes relied on foreign aid.
"Where technical issues arise, including those relating to data governance or agreement terms, these can often be resolved via detailed discussion and negotiated safeguards," it commented.
The situation highlights the complex debate between accepting crucial foreign assistance and protecting national sovereignty in an increasingly data-driven world.